BulgariaTuberculosis profile
Population  2015 7.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.09 (0.088–0.092) 1.3 (1.2–1.3)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0 (0–0.04)
Incidence  (includes HIV+TB) 1.7 (1.5–1.8) 24 (22–26)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.05 (0.05–0.06)
Incidence (MDR/RR-TB)** 0.1 (0.075–0.13) 1.4 (1–1.8)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.074 (0.052–0.096) 0.52 (0.37–0.67) 0.59 (0.42–0.76)
Males 0.062 (0.045–0.08) 1 (0.83–1.3) 1.1 (0.87–1.3)
Total 0.14 (0.11–0.16) 1.6 (1.5–1.6) 1.7 (1.5–1.8)
TB case notifications, 2015  
Total cases notified 1 660
Total new and relapse 1 619
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status  
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 65%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 96% (88–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.05 (0.05–0.06)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  80
(60–99)
Estimated % of TB cases with MDR/RR-TB 3.3% (2.1–5) 25% (18–33)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 1 789
Previously treated cases, excluding relapse, registered in 2014 56% 39
HIV-positive TB cases, all types, registered in 2014 33% 3
MDR/RR-TB cases started on second-line treatment in 2013 52% 33
XDR-TB cases started on second-line treatment in 2013 0% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 9%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 9.1
Funding source: 74% domestic, 26% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-02-23 Data: www.who.int/tb/data